Endo International (ENDP) Now Covered by B. Riley

Equities research analysts at B. Riley began coverage on shares of Endo International (NASDAQ:ENDP) (TSE:ENL) in a report issued on Wednesday. The brokerage set a “buy” rating and a $10.00 price target on the stock. B. Riley’s price target points to a potential upside of 58.23% from the company’s current price.

Several other research firms have also recently weighed in on ENDP. Royal Bank of Canada set a $9.00 price target on Endo International and gave the stock a “hold” rating in a report on Tuesday, October 17th. Zacks Investment Research cut Endo International from a “hold” rating to a “sell” rating in a report on Thursday, October 26th. Cantor Fitzgerald set a $9.00 price target on Endo International and gave the stock a “hold” rating in a report on Monday, October 30th. Citigroup reduced their price target on Endo International from $9.00 to $7.00 and set a “neutral” rating on the stock in a report on Friday, November 10th. Finally, BMO Capital Markets reduced their price target on Endo International from $11.00 to $10.00 and set a “market perform” rating on the stock in a report on Friday, November 10th. Three analysts have rated the stock with a sell rating, thirteen have issued a hold rating, five have assigned a buy rating and one has issued a strong buy rating to the stock. The stock currently has a consensus rating of “Hold” and an average price target of $10.51.

Endo International (NASDAQ:ENDP) opened at $6.32 on Wednesday. Endo International has a 12-month low of $5.77 and a 12-month high of $14.45. The company has a debt-to-equity ratio of 10.78, a current ratio of 1.08 and a quick ratio of 0.86. The stock has a market capitalization of $1,420.00, a PE ratio of -0.33, a price-to-earnings-growth ratio of 2.22 and a beta of 0.29.

Institutional investors have recently bought and sold shares of the stock. Macquarie Group Ltd. lifted its stake in shares of Endo International by 132.1% in the fourth quarter. Macquarie Group Ltd. now owns 6,500 shares of the company’s stock worth $107,000 after acquiring an additional 3,700 shares during the period. James Investment Research Inc. acquired a new position in shares of Endo International in the second quarter worth approximately $113,000. Blair William & Co. IL acquired a new position in shares of Endo International in the second quarter worth approximately $126,000. Point View Wealth Management Inc. lifted its stake in shares of Endo International by 12.3% in the first quarter. Point View Wealth Management Inc. now owns 11,431 shares of the company’s stock worth $128,000 after acquiring an additional 1,254 shares during the period. Finally, Oakbrook Investments LLC acquired a new position in shares of Endo International in the fourth quarter worth approximately $133,000. 92.42% of the stock is currently owned by institutional investors.

ILLEGAL ACTIVITY NOTICE: “Endo International (ENDP) Now Covered by B. Riley” was first published by American Banking News and is the sole property of of American Banking News. If you are accessing this piece of content on another site, it was copied illegally and reposted in violation of US and international copyright and trademark law. The original version of this piece of content can be viewed at https://www.americanbankingnews.com/2018/02/14/endo-international-endp-now-covered-by-b-riley.html.

Endo International Company Profile

Endo International PLC, formerly Endo Health Solutions Inc is a specialty healthcare solutions company focused on branded and generic pharmaceuticals, devices and services. The Company has a portfolio of branded pharmaceuticals that includes brands, such as Lidoderm, Opana ER, Voltaren Gel, Percocet, Frova, Supprelin LA, Vantas, Valstar and Fortesta Gel.

Analyst Recommendations for Endo International (NASDAQ:ENDP)

Receive News & Ratings for Endo International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endo International and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply